Anzeige
Mehr »
Login
Donnerstag, 21.11.2024 Börsentäglich über 12.000 News von 677 internationalen Medien
Von Solarenergie zu digitalen Assets: Die Strategie hinter der 75-Prozent-Rallye
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire
257 Leser
Artikel bewerten:
(0)

Annual Changes to the NASDAQ Biotechnology Index

Finanznachrichten News
NEW YORK, Dec. 14, 2018 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 24, 2018.

The following 60 securities will be added to the Index:
EXCHANGE	SYMBOL	COMPANY NAME
Nasdaq	ACIU	Ac Immune SA
Nasdaq	ACRX	AcelRx Pharmaceuticals, Inc.
Nasdaq	ADVM	Adverum Biotechnologies
Nasdaq	AGLE	Aeglea BioTherapeutics, Inc.
Nasdaq	AKRX	Akorn Inc.
Nasdaq	ALLK	Allakos Inc.
Nasdaq	AMRS	Amyris Inc.
Nasdaq	APLS	Apellis Pharma Inc.
Nasdaq	APTX	Aptinyx Inc.
Nasdaq	AQST	Aquestive Therapeutics
Nasdaq	ARGX	Argenx Se Ads
Nasdaq	ARQL	ArQule Inc.
Nasdaq	AUTL	Autolus Therapeutics Ltd.
Nasdaq	AVRO	AVROBIO Inc.
Nasdaq	CBAY	CymaBay Therapeutics
Nasdaq	CRNX	Crinetics Pharmaceuticals
Nasdaq	DCPH	Deciphera Pharmaceuticals
Nasdaq	DNLI	Denali Therapeutics Inc.
Nasdaq	DRNA	Dicerna Pharmaceuticals Inc.
Nasdaq	EIDX	Eidos Therapeutics Inc.
Nasdaq	EIGR	Eiger BioPharma
Nasdaq	ELOX	Eloxx Pharman
Nasdaq	EOLS	Evolus Inc.
Nasdaq	EYPT	EyePoint Pharma Inc.
Nasdaq	FATE	Fate Therapeutics Inc.
Nasdaq	FIXX	Homology Medicines Inc.
Nasdaq	FTSV	Forty Seven Inc.
Nasdaq	HCM	Hutchison China MediTech
Nasdaq	KNSA	Kiniksa Pharma Ltd.
Nasdaq	MGTA	Magenta Therapeutics
Nasdaq	MNOV	Medicinova Inc.
Nasdaq	MRTX	Mirati Therapeutics Inc.
Nasdaq	OCUL	Ocular Therapeutix Inc.
Nasdaq	OPTN	OptiNose Inc.
Nasdaq	PRQR	ProQR Therapeutics N.V.
Nasdaq	PTI	Proteostasis Therapeutic
Nasdaq	QTRX	Quanterix Corporation
Nasdaq	RCKT	Rocket Pharmaceuticals
Nasdaq	REPL	Replimune Group Inc.
Nasdaq	RUBY	Rubius Therapeutics
Nasdaq	RYTM	Rhythm Pharmaceuticals
Nasdaq	SIGA	SIGA Technologies Inc.
Nasdaq	SLDB	Solid Biosciences Inc.
Nasdaq	STIM	Neuronetics, Inc.
Nasdaq	SURF	Surface Oncology Inc.
Nasdaq	SYBX	Synlogic Inc.
Nasdaq	SYRS	Syros Pharmaceuticals
Nasdaq	TBIO	Translate Bio Inc.
Nasdaq	TCDA	Tricida Inc.
Nasdaq	TORC	resTORbio Inc.
Nasdaq	UBX	Unity Biotechnology
Nasdaq	UMRX	Unum Therapeutics Inc.
Nasdaq	URGN	UroGen Pharma Ltd.
Nasdaq	VSTM	Verastem Inc.
Nasdaq	WVE	Wave Life Sciences
Nasdaq	XENE	Xenon Pharmaceuticals
Nasdaq	XERS	Xeris Pharmaceuticals
Nasdaq	XON	Intrexon Corporation
Nasdaq	ZFGN	Zafgen Inc.
Nasdaq	ZLAB	Zai Lab Ltd.

The Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market® (NASDAQ®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB).

As a result of the re-ranking, the following 26 securities will be removed from the Index:
EXCHANGE	SYMBOL	COMPANY NAME
Nasdaq	AKAO	Achaogen Inc.
Nasdaq	ARDX	Ardelyx Inc.
Nasdaq	AVDL	Avadel Pharmaceuticals PLC
Nasdaq	BLCM	Bellicum Pharmaceuticals
Nasdaq	CALA	Calithera Biosciences
Nasdaq	CLDX	Celldex Therapeutics, Inc.
Nasdaq	CLXT	Calyxt, Inc.
Nasdaq	CMRX	Chimerix, Inc.
Nasdaq	CRIS	Curis Inc.
Nasdaq	CRVS	Corvus Pharma
Nasdaq	JNCE	Jounce Therapeutics, Inc.
Nasdaq	MRNS	Marinus Pharmaceuticals
Nasdaq	MRSN	Mersana Therapeutics
Nasdaq	NBRV	Nabriva Therapeutics PLC
Nasdaq	NEOS	Neos Therapeutics Inc.
Nasdaq	NH	NantHealth Inc.
Nasdaq	NK	NantKwest Inc.
Nasdaq	NLNK	NewLink Genetics Corporation
Nasdaq	RGEN	Repligen Corporation
Nasdaq	SGYP	Synergy Pharmaceuticals Inc.
Nasdaq	SHPG	Shire PLC
Nasdaq	SNDX	Syndax Pharmaceuticals
Nasdaq	SNNA	Sienna Biopharmaceuticals
Nasdaq	TLGT	Teligent Inc.
Nasdaq	TTPH	Tetraphase Pharmaceuticals Inc.
Nasdaq	VTL	Vital Therapies Inc.

About Nasdaq Global Indexes

Nasdaq Global Indexes has been creating innovative, market-leading, transparent indexes since 1971. Today, our index offering spans geographies and asset classes and includes diverse families such as the Dividend and Income (includes Dividend Achievers), Dorsey Wright, Fixed Income (includes BulletShares®), Global Equity, Green Economy, Nordic and Commodity indexes. We continuously offer new opportunities for financial product sponsors across a wide-spectrum of investable products and for asset managers to measure risk and performance. Nasdaq also provides exchange listing, custom index and design solutions to financial organizations worldwide.

About Nasdaq

Nasdaq (Nasdaq: NDAQ) is a leading global provider of trading, clearing, exchange technology, listing, information and public company services. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 100 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to over 4,000 total listings with a market value of approximately $15 trillion. To learn more, visit business.nasdaq.com.

The information contained above is provided for informational and educational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular financial product or an overall investment strategy. Neither The NASDAQ OMX Group, Inc. nor any of its affiliates makes any recommendation to buy or sell any financial product or any representation about the financial condition of any company or fund. Statements regarding Nasdaq’s proprietary indexes are not guarantees of future performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results. Investors should undertake their own due diligence and carefully evaluate companies before investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED.

NDAQG

Media Contacts:
Matthew Sheahan, Nasdaq
(212) 231-5945

Issuer & Investor Contact:
Natasha Selzer, Nasdaq
(301) 978-8623

Carla Proto, Nasdaq
(203) 926-3326
© 2018 GlobeNewswire
Treibt Nvidias KI-Boom den Uranpreis?
In einer Welt, in der künstliche Intelligenz zunehmend zum Treiber technologischer Fortschritte wird, rückt auch der Energiebedarf, der für den Betrieb und die Weiterentwicklung von KI-Systemen erforderlich ist, in den Fokus.

Nvidia, ein Vorreiter auf dem Gebiet der KI, steht im Zentrum dieser Entwicklung. Mit steigender Nachfrage nach leistungsfähigeren KI-Anwendungen steigt auch der Bedarf an Energie. Uran, als Schlüsselkomponente für die Energiegewinnung in Kernkraftwerken, könnte dadurch einen neuen Stellenwert erhalten.

Dieser kostenlose Report beleuchtet, wie der KI-Boom potenziell den Uranmarkt beeinflusst und stellt drei aussichtsreiche Unternehmen vor, die von diesen Entwicklungen profitieren könnten und echtes Rallyepotenzial besitzen

Handeln Sie Jetzt!

Fordern Sie jetzt den brandneuen Spezialreport an und profitieren Sie von der steigenden Nachfrage, der den Uranpreis auf neue Höchststände treiben könnte.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.